## Mini basket to go here ##
CF10 Cystinosis
The late Professor Rosaleen Anderson worked passionately on the design, synthesis and development of CF10 for the treatment of Nephropathic Cystinosis to overcome the problematic features of current Cystinosis treatments. Roz’s work was not confined purely to the laboratory. She made an effort to meet with children and families affected by Cystinosis, which she upheld, was an intrinsic part of her work. Sadly Roz passed away after a long battle with cancer in June 2018.
CF10 has been carefully constructed to
Improve pharmacokinetics
Reduce/eliminate adverse effects of cysteamine
What this means for patients:
Increased tolerability
- Improved palatability
- Reduced side effects compared with cysteamine
- Reduced frequency of dosing
Therefore
Better compliance
Delayed disease progression
Improved quality of life
What this means for healthcare professionals:
Reduced dosing frequency
- Improved pharmacokinetics
- Reduced side effects compared with cysteamine
Therefore
Better compliance
Better adherence to treatment regime
Improved tissue targeting for Cystinosis pathology
What this means for Healthcare Systems:
Increased treatment options
Revolutionised quality of life for patients and reduced burden on carers
Reduced burden on healthcare systems
Improved budget efficiency for healthcare systems
About Cystinosis
SUBSCRIBE
Receive updates and news